• 1
    Loftus EV Jr, Schoedenfeld P, Sandborn WJ. The epidemiology and natural history of Crohn’s disease in population-based patient cohorts from North America: a systemic review. Ailment Pharmacol Ther 2002; 16: 5160.
  • 2
    Management of Crohn’s disease in adults, Lichtenstein GR, Hanauer SB, Sandborn WJ. Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 2009; 104: 46583.
  • 3
    Travis SPL, Stange EF, Lémann M, et al. European evidence based consensus on the diagnosis and management of Crohn’s disease: current management. Gut 2006; 55(Suppl. 1): i1635.
  • 4
    Stange EF, Travis SPL, Vermeire S, et al. European evidence based consensus on the diagnosis and management of Crohn’s disease: definitions and diagnosis. Gut 2006; 55(Suppl. 1): 115.
  • 5
    Cohen RD. The quality of life in patients with Crohn’s disease. Ailment Pharmacol Ther 2002; 9: 16039.
  • 6
    Blondel-Kucharski F, Chircop C, Marquis P, et al. Health-related quality of life in Crohn’s disease: a prospective longitudinal study in 231 patients. Am J Gastroenterol 2001; 96: 291520.
    Direct Link:
  • 7
    Feagan BG, Bala M, Yan S, Olson A, Hanauer S. Unemployment and disability in patients with moderately to severely active Crohn’s disease. J Clin Gastroenterol 2005; 39: 3905.
  • 8
    Ananthakrishnan AN, Weber LR, Knox JF, et al. Permanent work disability in Crohn’s disease. Am J Gastroenterol 2008; 103: 15461.
  • 9
    Cohen RD, Larson LR, Roth JM, Becker RV, Mummert LL. The cost of hospitalization in Crohn’s disease. Am J Gastroenterol 2000; 95: 52430.
    Direct Link:
  • 10
    Longobardi T, Jacobs P, Bernstein CN. Work losses related to inflammatory bowel disease in the United States: results from the National Health Interview Survey. Am J Gastroenterol 2003; 98: 106472.
  • 11
    Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med 2003; 348: 6018.
  • 12
    Cheifetz A, Smedley M, Martin S, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 2003; 98: 131524.
    Direct Link:
  • 13
    Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn’s disease: a randomized controlled trial. Gastroenterology 2003; 124: 91724.
  • 14
    Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease. Clin Gastroenterol Hepatol 2004; 2: 54253.
  • 15
    Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002; 359: 15419.
  • 16
    Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC I trial. Gastroenterology 2006; 130: 32333.
  • 17
    Sandborn WJ, Hanauer SB, Rutgeerts PJ, et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut 2007; 56: 12329.
  • 18
    Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab. Ann Intern Med 2007; 146: 82938.
  • 19
    Colombel J-F, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology 2007; 132: 5265.
  • 20
    Irvine EJ, Zhou Q, Thompson AK. The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn’s Relapse Prevention Trial. Am J Gastroenterol 1996; 91: 15718.
  • 21
    Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993; 4: 35365.
  • 22
    Reilly MC, Brown MC, Brahant Y, Gerlier L, Tan SC, Sandborn WJ. Defining the minimally important difference for WPAI: CD Scores: What is a relevant impact on work productivity in active Crohn’s disease? Gut 2007; 56(Suppl. 3): A159.
  • 23
    Burmester GR, Mease P, Dijkmans BAC, et al. Adalimumab safety and mortality rates from trials of six immune mediated inflammatory diseases. Ann Rheum Dis 2009; 68: 18639.
  • 24
    Colombel J-F, Sandborn WJ, Panaccione R, et al. Adalimumab safety in global clinical trials of patients with Crohn’s disease. Inflamm Bowel Dis 2009; 15: 130819.
  • 25
    Rutgeerts P, D’Haens GR, Van Assche GA, et al. Adalimumab induces and maintains mucosal healing in patients with moderate to severe ileocolonic Crohn’s disease – first results of the EXTEND trial. Gastroenterology 2009; 5(Suppl. 1): A-116.
  • 26
    Feagan BG, Panaccione R, Sandborn WJ, et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn’s disease: results from the CHARM study. Gastroenterology 2008; 135: 14939.
  • 27
    Wu EQ, Yu AP, Tang J, Atanasov PD, Chao J, Mulani PM. Effect of sustained remission and clinical response on the risk of hospitalization in patients with Crohn’s disease. Manag Care Interface 2008; 21: 203.
  • 28
    Loftus EV, Feagan BG, Colombel J-F, et al. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn’s disease: patient-reported outcomes of the CHARM trial [published correction appears in Am J Gastroenterol 2009; 104: 1894]. Am J Gastroenterol 2008; 103: 313241.
    Direct Link:
  • 29
    HUMIRA® [Prescribing Information]. North Chicago, IL: Abbott Laboratories, 2010.
  • 30
    Seiderer J, Brand S, Dambacher J, et al. Adalimumab in patients with Crohn’s disease – safety and efficacy in an open-label single centre study. Aliment Pharmacol Ther 2007; 25: 78796.
  • 31
    Swaminath A, Ullman T, Rosen M, Mayer L, Lichtiger S, Abreu MT. Early clinical experience with adalimumab in treatment of inflammatory bowel disease with infliximab-treated and naïve patients. Aliment Pharmacol Ther 2009; 29: 2738.
  • 32
    Lofberg R, Louis E, Reinisch W, Kron M, Camez A, Pollack PF. Adalimumab effectiveness in TNF-antagonist–naïve Patients and in infliximab nonresponders with Crohn’s disease: results from the CARE study. Am J Gastroenterol 2008; 103(Suppl. 1): S418.
  • 33
    Van Assche G, Vermeire S, Rutgeerts P. Optimizing treatment of inflammatory bowel diseases with biologic agents. Curr Gastroenterol Rep 2008; 10: 5916.
  • 34
    Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomized trial. Lancet 2002; 359: 15419.
  • 35
    Sandborn WJ, Colombel JF, Schreiber S, et al. Dosage adjustment during long-term adalimumab treatment for Crohn’s disease: clinical efficacy and pharmacoeconomics. Inflamm Bowel Dis 2010 [Epub ahead of print].
  • 36
    Loftus EV Jr, Pan X, Zurawski P, et al. Dosage pattern of adalimumab in real-world clinical practice and predictors of dosage increase in patients with Crohn’s disease in the United States. Gastroenterology 2009; 5(Suppl. 1): A-1756.
  • 37
    Wu EQ, Mulani PM, Yu A, Tang J, Pollack PF. Loss of treatment response to infliximab maintenance therapy in Crohn’s disease: a payor perspective. Value Health 2008; 11: 8209.
  • 38
    Regueiro M, Siemanowski B, Kip KE, Plevy S. Infliximab dose intensification in Crohn’s disease. Inflamm Bowel Dis 2007; 13: 10939.
  • 39
    Ng SC, Plamondon S, Gupta A, Burling D, Kamm MA. Prospective assessment of the effect on quality of life of anti-tumour necrosis factor therapy for perineal Crohn’s fistulas. Aliment Pharmacol Ther 2009; 30: 75766.
  • 40
    Colombel JF, Schwartz DA, Sandborn WJ, et al. Adalimumab for the treatment of fistulas in patients with Crohn’s disease. Gut 2009; 58: 9408.
  • 41
    Reilly MC, Gerlier L, Brabant Y, Brown M. Validity, reliability, and responsiveness of the Work Productivity and Activity Impairment Questionnaire in Crohn’s disease. Clin Ther 2008; 30: 393404.